神经退行性痴呆中的价值生成探索性试验
针对阿尔茨海默病及其他神经退行性痴呆(含额颞叶痴呆)早期临床试验设计,本文讨论探索性试验(一般为1b或2a期)以生物标志物为结局、疗程更短、患者更少,可设go/no-go决策点、支持概念验证和剂量选择。阿尔茨海默病药物发现基金会与额颞叶变性协会召集顾问小组提出结局指标和统计考虑建议。
要点
- 探索性试验为1b/2a期,依赖生物标志物结局,疗程短、样本少。
- 探索性试验可设go/no-go决策点,支持概念验证和剂量选择。
- 早期失败可节省资源,对学术和小型生物技术公司尤为重要。
核心结论
- 探索性试验可在分期临床开发中提供有希望的数据,以支持推进化合物进入后期开发所需的资源。
- 探索性试验可终止未显示靶点结合且暴露合适、安全性可接受的药物,早期失败节省机会成本等宝贵资源。
研究设计与样本
- 本文讨论神经退行性痴呆的探索性临床试验,一般为1b期或2a期试验,设计用于评估药理效应并依赖生物标志物结局。
- 阿尔茨海默病药物发现基金会与额颞叶变性协会召集顾问小组,就结局指标和统计考虑提出建议。
主要发现
- 探索性试验与传统2期研究相比,治疗持续时间更短、患者更少。
- 探索性试验可建立go/no-go决策点,支持概念验证和剂量选择。
临床怎么用
- 在分期临床开发项目中采用探索性试验,可快速低成本获得概念验证,决定是否推进化合物。
- 对学术和小型生物技术公司项目尤为重要,也可用于大型制药公司高风险项目。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug development for Alzheimer disease and other neurodegenerative dementias, including frontotemporal dementia, has experienced a long history of phase 2 and phase 3 clinical trials that failed to show efficacy of investigational drugs. Despite differences in clinical and behavioral characteristics, these disorders have shared pathologies and face common challenges in designing early-phase trials that are predictive of late-stage success. Here, we discuss exploratory clinical trials in neurodegenerative dementias. These are generally phase 1b or phase 2a trials that are designed to assess pharmacologic effects and rely on biomarker outcomes, with shorter treatment durations and fewer patients than traditional phase 2 studies. Exploratory trials can establish go/no-go decision points, support proof of concept and dose selection, and terminate drugs that fail to show target engagement with suitable exposure and acceptable safety profiles. Early failure saves valuable resources including opportunity costs. This is especially important for programs in academia and small biotechnology companies but may be applied to high-risk projects in large pharmaceutical companies to achieve proof of concept more rapidly at lower costs than traditional approaches. Exploratory studies in a staged clinical development program may provide promising data to warrant the substantial resources needed to advance compounds through late-stage development. To optimize the design and application of exploratory trials, the Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration convened an advisory panel to provide recommendations on outcome measures and statistical considerations for these types of studies and study designs that can improve efficiency in clinical development.
引用
- Friedman LG, McKeehan N, Hara Y, et al. Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology. 2021. PMID: 33674360. doi:10.1212/WNL.0000000000011774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。